Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Taysha Gene Therapies (NASDAQ:TSHA) had its price objective increased by stock analysts at Robert W. Baird from $12.00 to $15.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price objective suggests a potential upside of 122.88% from the company’s current price.

Several other equities research analysts also recently weighed in on TSHA. Citizens Jmp increased their price target on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 23rd. Chardan Capital restated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Wednesday, June 24th. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, BMO Capital Markets lifted their target price on Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus target price of $12.62.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ:TSHA opened at $6.73 on Tuesday. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -17.71 and a beta of 1.19. Taysha Gene Therapies has a 12 month low of $2.25 and a 12 month high of $7.30. The firm’s 50-day moving average is $6.13 and its 200 day moving average is $5.30. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Research analysts predict that Taysha Gene Therapies will post -0.5 EPS for the current year.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the completion of the sale, the insider owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. The trade was a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC raised its position in Taysha Gene Therapies by 325.6% during the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after purchasing an additional 82,545 shares in the last quarter. Rhumbline Advisers grew its position in shares of Taysha Gene Therapies by 13.5% during the 2nd quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock worth $539,000 after buying an additional 27,794 shares in the last quarter. Prudential Financial Inc. increased its stake in shares of Taysha Gene Therapies by 50.5% during the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock valued at $53,000 after buying an additional 7,650 shares during the period. Invesco Ltd. increased its stake in shares of Taysha Gene Therapies by 27.4% during the second quarter. Invesco Ltd. now owns 203,671 shares of the company’s stock valued at $470,000 after buying an additional 43,772 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of Taysha Gene Therapies in the second quarter valued at about $184,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.